Cargando…
Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer
Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies with various clinical presentations and evolution. NETs are often diagnosed at a late stage, when they are already metastatic. Treatment is currently based on traditional chemotherapies, such as streptozocin, with serious si...
Autores principales: | Faure, Marjorie, Niccoli, Patricia, Autret, Aurelie, Cavaglione, Gerard, Mineur, Laurent, Raoul, Jean-Luc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245060/ https://www.ncbi.nlm.nih.gov/pubmed/28123727 http://dx.doi.org/10.3892/mco.2016.1097 |
Ejemplares similares
-
An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value
por: Andriantsoa, Maeva, et al.
Publicado: (2017) -
FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023) -
A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
por: Takeuchi, Satoshi, et al.
Publicado: (2011) -
A single-center experience with pancreatic cystic neuroendocrine tumors
por: Khalil, Ange, et al.
Publicado: (2020) -
Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)